Carbonic Anhydrase Inhibitors in Glaucoma Management

Identification through Packaging:
- Topical carbonic anhydrase inhibitors are traditionally identified by an orange cap on the medication bottle.
- Caveat: Users should not rely entirely on the color of the cap, especially with generic medications, as labeling can vary.
Historical Context:
- Oral carbonic anhydrase inhibitors have been used clinically for decades.
- Despite their longevity, their use is significantly limited by systemic side effects, which can be severe.
Individual Variability:
- There is a marked difference in how individuals tolerate these medications.
- While many patients struggle with side effects, some have been taking oral CAIs for "years and years" without significant issues.

Primary Mechanism:
- CAIs act as aqueous production inhibitors.
- They work by inhibiting the enzyme carbonic anhydrase within the ciliary body of the eye.
Enzyme Inhibition Threshold:
- To effectively decrease aqueous production, a significant level of enzyme inhibition is required.
- It is generally estimated that at least $90\%$ to $99\%$ of carbonic anhydrase must be inhibited to achieve a reduction in intraocular pressure (IOP).
Circadian Efficacy:
- Unlike other glaucoma medications such as beta-blockers ( $\text{e.g., timolol}$ ) or alpha agonists ( $\text{e.g., brimonidine}$ ), CAIs are effective during both the day and the night.
Comparison of Efficacy by Route:
- Oral Administration: Can lower intraocular pressure by up to $50\%$ .
- Topical Administration: More typically lowers intraocular pressure by $15\%$ to $20\%$ .
- Topical versions are generally less effective than systemic versions but are much better tolerated.

General Use:
- Like beta-blockers, CAIs are aqueous inhibitors and are useful for treating all forms of glaucoma.
Corneal Endothelium Concerns:
- CAIs may not be ideal for patients with a failing corneal endothelium, such as those with Fuchs' dystrophy.
- Reasoning: The medication inhibits the corneal endothelial pump, which is necessary for maintaining corneal clarity.
Renal and Metabolic Precautions:
- Kidney Stones: Oral CAIs should be avoided in patients with a history of kidney stones, with acetazolamide being a particular concern.
- Diuretic Interaction: Caution is required for patients taking oral diuretics as the combination can lead to hypokalemia (low potassium levels).

Chemical Relationship:
- Carbonic anhydrase inhibitors are sulfonamide derivatives, leading to frequent warnings regarding sulfa allergies.
Clinical Evidence and Recommendations:
- A recent Medical Letter published research suggesting that topical CAIs are safe to use in patients with sulfa allergies.
- A large study by Andy Lee and colleagues focused on patients with idiopathic intracranial hypertension and self-reported sulfa allergies. The study used doses much larger than those typically used in glaucoma treatment and found the medication was well-tolerated.
- While the speaker advises not to ignore a sulfa allergy, they do not let it prevent them from prescribing topical CAIs.
- Evidence suggests that even systemic CAIs may be safe for people with sulfa allergies, though they would not be the first choice.

Topical Side Effects:
- Bitter Taste: A common complaint, though usually tolerable.
- Stinging: Occurs more frequently with dorzolamide than with brinzolamide.
Oral (Systemic) Side Effects:
- Paresthesias: Tingling sensations in the fingers and toes; experienced by almost every patient.
- Metallic Taste: Altered taste sensation, particularly for carbonated beverages.
- Altered Carbonation Perception: Soda pop and beer may taste "flat and funny."
- General Malaise and Weight Loss: Significant enough to be reasons for discontinuing the drug.
- Hypokalemia: Decreased potassium levels, especially when combined with systemic diuretics.
- Metabolic Acidosis: A change in the body's acid-base balance.
- Kidney Stones: More likely with acetazolamide than with methazolamide.
- Hematologic Reactions: Rare but fatal idiosyncratic reactions, including aplastic anemia.

Available Monotherapies (USA):
- Dorzolamide: Known to cause more stinging upon application.
- Brinzolamide: Formulated as a suspension. It may leave white particulate matter on the eyelashes, though this rarely bothers patients clinically.
- Dosing: Typically administered $2$ or $3$ times a day.
Combination Therapies:
- Dorzolamide combined with timolol.
- Brinzolamide combined with brimonidine.

Acetazolamide (Diamox):
- Formulations: available as $250\,mg$ tablets (cheaper but less tolerated) or sustained-release capsules (better tolerated).
- Alternative Administrations: Can be given intravenously (IV) or prepared as a syrup for pediatric use.
- Dosing: Tablets are given $2$ to $4$ times per day; sustained-release capsules are given twice a day.
- Excretion: Primarily excreted in the urine.
- Caution: Not the best choice for patients with kidney disease due to the higher risk of renal stones.
Methazolamide (Neptazane):
- Formulation: Available as a pill.
- Metabolism: Processed in the liver.
- Advantage/Risk: May be safer for those with kidney disease but should be avoided in patients with liver disease.
- Dosing: Administered $2$ or $3$ times a day.
Clinical Preference:
- The speaker tends to start with methazolamide because it is generally better tolerated than acetazolamide. If the patient tolerates it but needs more effect, they may transition to acetazolamide.

Declining Use of Systemics:
- The systemic form is used less often today because of poor patient tolerance and a decreasing level of comfort/familiarity among modern ophthalmologists.
Specific Clinical Scenarios for Oral CAIs:
- To "tide a patient over" while they are waiting for surgery.
- For patients unable to undergo surgery for any reason.
- In "desperate" situations where all other medical options have been exhausted.